- +62 21 29189160 (ext. 201912)
- manajer.riset.fkui1@gmail.com
- Senin-Jum'at 8.00 s/d 16.00 WIB
Publikasi Scopus 2024 per tanggal 31 Mei 2024 (409 artikel)
Publikasi Scopus 2024 per tanggal 31 Mei 2024 (409 artikel)
Suryana, Bagus Putu Putra (15728721800); Hidayat, Rudy (37067327300); Sarmidi, Sumariyono (58865874000); Wibowo, Suryo Anggoro Kusumo (57477727300); Hamijoyo, Laniyati (25936059700); Rahmadi, Andri Reza (57211655175); Marpaung, Blondina (57192888311); Ginting, Andi Raga (57215378335); Kambayana, Gede (57219746061); Kurniari, Pande Ketut (57371164900); Sylvawani, Mahriani (57225078775); Najirman (58866983800); Suarjana, Nyoman (58867206800); Achadiono, Deddy Nur Wachid (54893129100); Rahmawati, L
Characteristics and prevalence of clinical remission of rheumatoid arthritis in a nationwide study from Indonesia
2024
International Journal of Rheumatic Diseases
27
2
e15050
1
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184193597&doi=10.1111%2f1756-185X.15050&partnerID=40&md5=a4f93ec847a80121dbfe5c302eb1c35b
Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Brawijaya, Saiful Anwar General Hospital, Malang, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Sumatera Utara, Medan, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Udayana, Sanglah General Hospital Denpasar, Bali, Denpasar, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Syah Kuala, Banda Aceh, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Andalas, Padang, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Lambung Mangkurat, Banjarmasin, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Airlangga, Dr Soetomo General Hospital, Surabaya, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Diponegoro, Dr Kariadi General Hospital, Semarang, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Sebelas Maret, Dr Moewardi General Hospital, Solo, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Sriwijaya, Mohammad Hoesin General Hospital, Palembang, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Hasanudin, Makassar, Indonesia; Rheumatology Division Department of Internal Medicine, Faculty of Medicine Universitas Sam Ratulangi, Manado, Indonesia; Department of Internal Medicine, Kanujoso Djatiwibowo General Hospital, Balikpapan, Indonesia
Aim: To investigate the clinical characteristics, DMARD treatment pattern, remission rate, and factors associated with disease remission of rheumatoid arthritis (RA) patients in Indonesia. Method: A multicenter survey was conducted in 2019–2020 involving 16 hospitals in Indonesia. Inclusion criteria were RA patients who fulfilled the 2010 ACR/EULAR classification criteria, were aged ≥18 years, and have been treated with 1 DMARD or more for at least 6 months, with exclusion criteria being the co-existence of other autoimmune diseases or pain syndromes. Disease activities and remission rate were defined using DAS28-ESR. Results: A total of 870 patients were completed for analysis. Remission was achieved in 24.5% of patients, while low disease activity in 18.5%, moderate disease activity in 44.6%, and high disease activity in 12.4%. The distribution of conventional DMARDs from subjects was methotrexate 69.9%, leflunomide 15.9%, sulfasalazine 12.0%, chloroquine/hydroxychloroquine 8.9%, and cyclosporine 4.8%. Patients treated with biologic DMARDs were only 0.3%. The mean methotrexate dose was 11.2 ± 4.0 mg/week, and the mean methotrexate duration was 45.1 ± 36.6 months. The majority of patients received glucocorticoids (65.5%). 71.1% received DMARD monotherapy, while 28.9% had combined DMARDs. According to the multivariate analysis, delayed time to diagnosis and treatment (>6 months), DMARD monotherapy, and glucocorticoid use were negatively associated with disease remission. Conclusion: The remission rate of Indonesian RA patients is 24.5%, and low disease activity is 18.5%. Methotrexate and leflunomide are the most frequent conventional DMARDs used. Delayed diagnosis, delayed treatment, and DMARD monotherapy contributed to the current low remission rate in Indonesia. © 2024 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
chloroquine; cyclic citrullinated peptide antibody; disease modifying antirheumatic drug; glucocorticoid; hydroxychloroquine; leflunomide; methotrexate; methylprednisolone; rheumatoid factor; salazosulfapyridine; adult; Article; autoimmune disease; body mass; DAS28; delayed diagnosis; disease activity; disease duration; educational status; erythrocyte sedimentation rate; female; human; major clinical study; male; monotherapy; multicenter study; observational study; prevalence; remission; retrospective study; rheumatoid arthritis; smoking; therapy delay; visual analog scale
Queen Mary Hospital
The authors thank all Indonesian Rheumatology Association (IRA) members for contributing to this study. The authors also thank all the physicians and residents who helped sample the patients in this study. Also thank you very much for Chak Sing Lau from Queen Mary Hospital, University of Hong Kong for comments and suggestions in improving this article.
John Wiley and Sons Inc
17561841
Article
Q3
715
6929
© 2024 Riset & Pengabdian Masyarakat. All Rights Reserved.